Home / Market News / $LUNG
fiscal.ai Corporate Catalyst Impact 65/100 ● neutral

Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal® System

Nov 17, 2026, 2:12 PM UTC · Primary ticker $LUNG

Pulmonx announced the publication of positive CONVERT trial results for its AeriSeal System, demonstrating its effectiveness in preparing emphysema patients for Zephyr Valve treatment. This news validates the potential of a key product and could positively impact investor sentiment regarding the company's growth prospects and competitive position.

Pulmonx announced the publication of positive results from its CONVERT trial for the AeriSeal System. The study showed that 75.8% of patients successfully converted to collateral ventilation-negative status, enabling subsequent treatment with Zephyr Valves, which led to clinically significant lung volume reduction. This is a positive development for Pulmonx as it validates the efficacy of their AeriSeal System, potentially expanding the addressable market for their Zephyr Valves by making more patients eligible. For traders, this news could lead to short-term positive sentiment and increased investor confidence in LUNG, as it de-risks a key product in their pipeline and supports future growth. The ongoing CONVERT II pivotal trial will be the next significant catalyst, building on these promising findings.

$LUNG positive Positive clinical trial results for key product
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.